The Rescue Line: What Surgery Delivers After an Incretin Fails

A Cleveland Clinic cohort of 4,929 patients is the first to measure two-year weight loss by the reason a semaglutide or tirzepatide prescription ended — and the procedure gap it reports is far wider than the group averages suggest.

bariatric surgeryGLP-1weight lossaccess to care

Incretin therapy changed the order of operations. For most adults with obesity and type 2 diabetes today, the first treatment offered is a weekly injection, not a referral to a surgeon. What the field has lacked is a measurement of the second step: what happens to the people who take the drug, stop it, and then go under the knife anyway.

A retrospective cohort published online on 3 November in Annals of Surgery supplies one. Ali Aminian and colleagues at the Cleveland Clinic looked at 4,929 adults with a BMI of at least 35 kg/m² who had a sleeve gastrectomy or a Roux-en-Y gastric bypass at the system’s hospitals between 2018 and 2024, and sorted them by what had happened with semaglutide or tirzepatide beforehand. Most — 4,661 — had no prior exposure. Sixty-one had stopped an incretin because of intolerable side effects. Two hundred and seven had what the authors call an inadequate weight-loss response.

Before surgery, the two medication groups were not people for whom the drugs had half-worked. The model’s estimate of two-year weight change while on treatment was a 1.4% gain in the intolerance group and a 1.5% loss in the inadequate-response group — near enough to standing still, given how the same agents perform in trials.

What the operating room delivered

Two years after surgery, total body weight loss split by procedure and by diabetes status in a pattern that is worth reading slowly.

GroupBypass, no T2DMBypass, with T2DMSleeve, no T2DMSleeve, with T2DM
Stopped for intolerance (n=61)27.9%22.7%20.1%21.6%
Inadequate response (n=207)35.8%27.4%14.3%14.2%
No prior incretin (n=4,661)33.3%28.7%23.6%19.9%

Model-estimated two-year total body weight loss.

Read across the top row and the story is unremarkable: surgery worked about as well in people who could not tolerate the drug as it did in people who had never been offered one. Read the middle row and it stops being unremarkable. In the inadequate-response group, bypass outcomes were as good as or better than the drug-naive comparator’s, while sleeve outcomes fell well below it — a 14.3% two-year loss in patients without diabetes, against 23.6% among unexposed sleeve patients.

Within the inadequate-response group, the adjusted comparison puts bypass at 32.7% two-year weight loss against 17.8% for the sleeve — a difference of 14.9 percentage points (95% CI 13.1 to 16.7). That is a large gap to place on 207 people split into four cells, in a study where nobody was randomised and surgeons chose the operation. A sleeve is a fixed, restrictive pouch; a bypass adds hormonal and malabsorptive effects. Appetite already reshaped by an incretin might respond differently to each — or the surgeons may simply have reached for the more definitive operation in patients they judged most likely to need it. The paper does not separate those readings, and its conclusion stays at “potentially offering greater benefit.”

A smaller pipeline, arriving later

The context in which these referrals happen is documented separately, in a nationwide analysis of the Epic Cosmos database published in Surgical Endoscopy in September. Between 2018 and 2025, primary sleeve and bypass volume peaked in the fourth quarter of 2022 and then fell 39% through the end of 2025. Over the same window, the share of surgical patients who had received a GLP-1 receptor agonist before their operation rose from 0.2% to 35.3%.

Who arrives pre-treated is not random. Prior incretin use was associated with private insurance, White race, older age, type 2 diabetes (relative risk 2.94), sleep apnoea and steatotic liver disease. Patients who had surgery first were more often Hispanic or Black and more often publicly insured or uninsured. After adjustment for patient characteristics and year, the odds of a pre-surgery GLP-1 prescription still varied 15-fold between the highest and lowest hospitals.

If the choice between medication-first and surgery-first varies fifteenfold across centres after adjusting for who the patients are, then a good part of the “rescue” pathway is institutional habit rather than clinical indication — and the queue a patient joins may depend more on which hospital’s door they walk through than on their HbA1c.

A smaller Spanish series in Obesity Research & Clinical Practice pushes from the other direction. Among 86 patients at a single Madrid centre, the third who had received a GLP-1 agonist before surgery lost more weight preoperatively (5.1% versus 2.4%) and marginally more at one month, but the difference was gone by six months, with no lean-mass penalty. Starting earlier did not compound into a better surgical result.

The reverse sequence has been examined more thoroughly than this one: starting an incretin after the operation, as adjuvant therapy or as rescue for weight regain, is the subject of a body of trial and cohort work reviewed here in October. That literature is where most of the practical guidance sits, and it is where the measurement problem is sharpest — how much weight loss you credit to the drug depends on whether you count from the patient’s weight on the day of surgery or from their preoperative peak.

What the study cannot see

The cohort is one health system’s electronic record, with exposure and response classified from prescriptions and dispensing data — a reasonable proxy, and still a proxy. Its two-year weights are model-estimated rather than counted. And its comparator for a failed drug is surgery, when in practice the alternative is often a different agent, a higher dose, or a switch from semaglutide to tirzepatide; no randomised trial has compared surgery with optimized pharmacotherapy in inadequate responders. Several authors disclose industry funding, including the senior author’s trial grants.

Eligibility is not what is in dispute here. NIDDK’s patient information puts surgery forward as a possible option at a BMI of 40 or more, or 35 or more with a serious obesity-related health problem — the arithmetic behind our BMI calculator — and everyone in the Cleveland Clinic cohort had already cleared it.

What the cohort does establish is narrower and still useful: an operation performed after an incretin was abandoned is not a salvage procedure with degraded returns. Two-year weight loss in the intolerance group landed within a few points of the drug-naive comparator, and glycaemic and safety outcomes will need their own follow-up papers before anyone claims more than that.

For scale and durability, the reference point remains the LABS study, funded by NIDDK — a six-centre prospective cohort that followed 4,776 participants with a mean BMI of 46.5 from operations performed in 2005–2007, and reported an average 28.4% weight loss seven years after gastric bypass and 14.9% after gastric band. That archive is where the field’s expectations for long-horizon outcomes were set, and it is an independent project we document rather than represent. It also carries one caveat that matters here: the sleeve, now the most common operation in the United States, was too uncommon during the study years to be included in those results. The operation most patients now receive after a failed injection has never had a LABS of its own.

This site is an independent archive and is not affiliated with, endorsed by, or speaking for the National Institutes of Health or NIDDK. This article reports published research; it is not medical advice, and questions about treatment belong with a clinician.

Sources

  1. Bariatric Surgery as a Rescue Strategy After Semaglutide or Tirzepatide (Annals of Surgery, 3 November 2026)
  2. Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide (Surgical Endoscopy, 2026)
  3. GLP-1 receptor agonist therapy before bariatric surgery: effects on weight loss and body composition in clinical practice (Obesity Research & Clinical Practice, 2026)
  4. NIDDK — Weight-loss (Metabolic & Bariatric) Surgery
  5. NIDDK — Long-term Study of Bariatric Surgery for Obesity: LABS
From the blog

New research notes